Poly Medicure Limited (POLYMED) AI Stock Analysis

• Market Cap: ₹197.94B
• Dividend Yield: 0.19%
• Average Volume (3M): 8.86K
• Price to Earnings (P/E): 54.7
• Beta (1Y): 0.98
• Revenue Growth: 12.46%
• EPS Growth: 16.66%
• Country: IN
• Employees: 6,300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 9.10
• Shares Outstanding: 101,359,490
• 10 Day Avg. Volume: 7,511
• 30 Day Avg. Volume: 8,860
• PEG Ratio: 2.36
• Price to Book (P/B): 7.72
• Price to Sales (P/S): 12.79
• P/FCF Ratio: -235.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: ₹2,294.00 ▲(19.22% Upside)

Poly Medicure Limited's strong financial performance and positive technical indicators are offset by a high valuation, suggesting potential overvaluation. The company's robust financial health and market momentum are significant strengths, but the high P/E ratio and low dividend yield are notable risks.

Poly Medicure Limited Business Overview & Revenue Model

Company Description

Poly Medicure Limited manufactures and sells medical devices. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extension sets, stylet/mandrin with luer locks, vial access spikes, measured volume fluid administration sets, extension lines, central venous catheters, CVP manometers, needle free connectors, pre filled syringes, vascular accesses, and blood administration sets. The company also provides nasogastric and infant feeding tubes, gastro-duodenal feeding tubes, and umbilical catheters; urine collection bags, foley balloon catheters, irrigation sets, urine drainage catheters, and urine collection bags with measured volume meters; and endotracheal tubes, tracheostomy tubes, mucus extractors, ventilator circuits, bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. In addition, it offers oncology products; endo bronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oro-pharyngeal airways, variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, and aerosol therapy masks; and dialyzers, blood lines, dialysis systems, fistula needles, haemodialysis catheters, and peritoneal dialysis and transfusion sets. Further, it provides closed wound suction units, under water seal drainage systems, high pressure vacuum bottles, yankauer suction sets, and thoracic drainage catheters; blood collection tubes, safety blood collection sets, blood collection needles, erythrocyte sedimentation rate pipettes, and luer adaptors; blood bag systems; face protective shields, polymasks, and viral transport medium kits; and insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, and universal caps. The company was incorporated in 1995 and is based in New Delhi, India.

How the Company Makes Money

Poly Medicure Limited generates revenue through the sale of its medical devices and consumables, which are distributed to hospitals, clinics, and healthcare providers both domestically and internationally. The company's revenue model is primarily based on direct sales and distribution agreements. Key revenue streams include the sale of intravenous sets, catheters, and other disposable medical products. POLYMED also engages in strategic partnerships with healthcare institutions and distributors, which help expand its market reach and enhance brand visibility. The company's focus on research and development fosters innovation, enabling it to introduce new products that meet evolving healthcare needs, thereby driving additional revenue growth.

Poly Medicure Limited Financial Statement Overview

Summary

Poly Medicure Limited exhibits strong financial health with consistent revenue growth and solid profitability margins. The balance sheet reflects financial stability with low leverage and increasing equity. However, negative free cash flow due to high capital expenditures highlights the need for careful capital management.

Income Statement

Poly Medicure Limited's income statement reveals impressive revenue growth, with a consistent upward trajectory from 2020 to 2025. The gross profit margin remains strong, reflecting efficient cost management and a solid market position. The net profit margin has also improved, indicating enhanced profitability. However, the EBIT margin shows some fluctuation, suggesting variability in operational efficiency.

Balance Sheet

The balance sheet of Poly Medicure Limited indicates solid financial stability, with a low debt-to-equity ratio that underscores prudent financial management. The company has consistently increased its stockholders' equity, supporting a strong equity ratio. However, despite these strengths, the company's asset base has grown significantly, which could suggest potential capital inefficiencies.

Cash Flow

Poly Medicure Limited's cash flow statements demonstrate a robust operating cash flow, which is a positive indicator of the company's ability to generate cash from its core operations. However, the free cash flow has been negative in recent years due to high capital expenditures, which could pose a risk if not managed carefully. The cash flow from investing activities suggests significant reinvestment into the business, which may drive future growth.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.88B	16.70B	13.76B	11.15B	9.23B	7.86B
Gross Profit	11.30B	11.11B	8.89B	7.06B	5.72B	5.23B
EBITDA	4.47B	4.52B	3.58B	2.68B	2.12B	2.13B
Net Income	3.58B	3.39B	2.58B	1.79B	1.47B	1.36B
Balance Sheet
Total Assets	0.00	31.92B	18.59B	15.77B	13.77B	12.24B
Cash, Cash Equivalents and Short-Term Investments	12.08B	12.08B	2.86B	3.01B	3.52B	3.74B
Total Debt	0.00	1.80B	1.74B	1.49B	1.27B	1.37B
Total Liabilities	-27.66B	4.27B	3.89B	3.36B	2.89B	2.58B
Stockholders Equity	27.66B	27.66B	14.70B	12.42B	10.87B	9.66B
Cash Flow
Free Cash Flow	0.00	-906.06M	-109.34M	-484.49M	-321.05M	236.01M
Operating Cash Flow	0.00	2.40B	2.66B	1.91B	1.23B	1.19B
Investing Cash Flow	0.00	-11.94B	-2.41B	-1.79B	-853.32M	-4.36B
Financing Cash Flow	0.00	9.51B	-201.53M	-125.05M	-353.38M	3.17B

Poly Medicure Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1924.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:POLYMED, the sentiment is Negative. The current price of 1924.1 is below the 20-day moving average (MA) of 1934.47, below the 50-day MA of 1935.01, and below the 200-day MA of 2139.41, indicating a bearish trend. The MACD of -8.53 indicates Positive momentum. The RSI at 47.97 is Neutral, neither overbought nor oversold. The STOCH value of 22.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:POLYMED.

Poly Medicure Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
POLYMED	72 Outperform	₹197.94B	54.74	―	0.19%	12.46%	16.66%
GLAND	66 Neutral	₹315.14B	39.87	―	1.00%	-1.51%	14.27%
GLAXO	63 Neutral	₹450.87B	47.45	―	2.18%	4.17%	41.51%
ERIS	61 Neutral	₹217.89B	56.27	―	0.44%	20.02%	19.17%
APLLTD	60 Neutral	₹177.69B	28.01	―	1.22%	11.42%	-1.91%
GLENMARK	53 Neutral	₹521.13B	69.14	―	0.27%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Poly Medicure Limited Corporate Events

Poly Medicure Limited Announces Acquisition of PendraCare Group

Poly Medicure Limited announced its proposed acquisition of the PendraCare Group, based in Amsterdam, Netherlands. This strategic move, discussed in a recent investor and analyst conference call, is expected to enhance Poly Medicure’s market position and expand its product offerings in the European market, potentially benefiting stakeholders through increased market share and operational synergies.

Poly Medicure Limited Announces Virtual AGM and Shareholder Engagement Initiatives

Poly Medicure Limited has announced the dispatch of letters to shareholders whose email addresses are not registered with the company or depositories, informing them about the upcoming Annual General Meeting (AGM) scheduled for September 25, 2025. The AGM will be conducted via video conferencing, and shareholders are encouraged to update their KYC details. The announcement also includes details about the final dividend for the fiscal year 2024-25, e-voting procedures, and the availability of the annual report and AGM notice online, reflecting the company’s commitment to maintaining transparency and shareholder engagement.